| [1] |
CUNNINGHAM ME, PARASTANDEH-CHEHR G, CEROCCHI O, et al. Noninvasive predictors of high-risk varices in patients with non-cirrhotic portal hypertension[J]. Can J Gastroenterol Hepatol, 2019, 2019: 1808797. DOI: 10.1155/2019/1808797. |
| [2] |
KHANNA R, SARIN SK. Non-cirrhotic portal hypertension-diagnosis and management[J]. J Hepatol, 2014, 60(2): 421-441. DOI: 10.1016/j.jhep.2013.08.013. |
| [3] |
SIRAMOLPIWAT S, SEIJO S, MIQUEL R, et al. Idiopathic portal hypertension: natural history and long-term outcome[J]. Hepatology, 2014, 59(6): 2276-2285. DOI: 10.1002/hep.26904. |
| [4] |
|
| [5] |
de FRANCHIS R. Expanding consensus in portal hypertension: report of the Baveno Ⅵ Consensus Workshop: stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022. |
| [6] |
DELEVE LD, VALLA DC, GARCIA-TSAO G, et al. Vascular disorders of the liver[J]. Hepatology, 2009, 49(5): 1729-1764. DOI: 10.1002/hep.22772. |
| [7] |
LI H, SUN PM, SUN HW, et al. Progress in clinical diagnosis and treatment of cavernous transformation of the portal vein[J]. World Chin J Dig, 2021, 29(12): 662-669. DOI: 10.11569/wcjd.v29.i12.662j. |
| [8] |
RUNGJIRAJITTRANON T, OWATTANAPANICH W, UNGPRASERT P, et al. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms[J]. BMC Cancer, 2019, 19(1): 184. DOI: 10.1186/s12885-019-5387-9. |
| [9] |
LEVINE RL, WADLEIGH M, COOLS J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis[J]. Cancer Cell, 2005, 7(4): 387-397. DOI: 10.1016/j.ccr.2005.03.023. |
| [10] |
MCCLURE R, MAI M, LASHO T. Validation of two clinically useful assays for evaluation of JAK2V617F mutation in chronic myeloproliferative disorders[J]. Leukemia, 2006, 20(1): 168-171. DOI: 10.1038/sj.leu.2404007. |
| [11] |
SUN CC, LI Y, TIAN WJ, et al. JAK2V617F mutation and TNF-α expression in myeloproliferative neoplasms and their correlation[J]. J Exp Hematol, 2014, 22(4): 1022-1026. DOI: 10.7534/j.issn.1009-2137.2014.04.025. |
| [12] |
TEFFERI A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management[J]. Am J Hematol, 2018, 93(12): 1551-1560. DOI: 10.1002/ajh.25230. |
DownLoad:
